Weaver Capital Management LLC Has $609,000 Stock Position in Agilent Technologies, Inc. (NYSE:A)

Weaver Capital Management LLC raised its position in Agilent Technologies, Inc. (NYSE:A) by 37.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,531 shares of the medical research company’s stock after acquiring an additional 1,231 shares during the period. Weaver Capital Management LLC’s holdings in Agilent Technologies were worth $609,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in A. Van ECK Associates Corp raised its holdings in shares of Agilent Technologies by 6.6% in the 3rd quarter. Van ECK Associates Corp now owns 2,976,905 shares of the medical research company’s stock worth $442,011,000 after buying an additional 183,716 shares in the last quarter. Vestal Point Capital LP acquired a new position in shares of Agilent Technologies in the 3rd quarter worth approximately $14,848,000. Empowered Funds LLC raised its holdings in shares of Agilent Technologies by 29.8% in the 3rd quarter. Empowered Funds LLC now owns 30,978 shares of the medical research company’s stock worth $4,592,000 after buying an additional 7,111 shares in the last quarter. S.E.E.D. Planning Group LLC raised its holdings in shares of Agilent Technologies by 12.7% in the 4th quarter. S.E.E.D. Planning Group LLC now owns 42,587 shares of the medical research company’s stock worth $5,721,000 after buying an additional 4,805 shares in the last quarter. Finally, Czech National Bank grew its position in Agilent Technologies by 6.5% during the 3rd quarter. Czech National Bank now owns 59,456 shares of the medical research company’s stock worth $8,828,000 after acquiring an additional 3,612 shares during the last quarter.

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,911 shares of Agilent Technologies stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the transaction, the chief executive officer now owns 39,652 shares in the company, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Analysts Set New Price Targets

A number of research firms recently commented on A. Citigroup increased their price target on Agilent Technologies to $165.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th. Barclays decreased their price target on Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating on the stock in a research report on Wednesday, November 27th. Bank of America decreased their price objective on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. StockNews.com upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Finally, JPMorgan Chase & Co. decreased their price objective on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $143.62.

Agilent Technologies Stock Performance

A opened at $147.06 on Wednesday. The business’s 50-day moving average price is $140.80 and its two-hundred day moving average price is $138.96. Agilent Technologies, Inc. has a 1 year low of $124.16 and a 1 year high of $155.35. The company has a market capitalization of $42.00 billion, a price-to-earnings ratio of 33.27, a P/E/G ratio of 4.10 and a beta of 1.07. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Monday, November 25th. The medical research company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.41 by $0.05. The company had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. Agilent Technologies’s revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter last year, the company earned $1.38 EPS. Equities analysts expect that Agilent Technologies, Inc. will post 5.56 EPS for the current fiscal year.

Agilent Technologies Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 22nd. Stockholders of record on Tuesday, December 31st were issued a $0.248 dividend. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend was Tuesday, December 31st. This represents a $0.99 annualized dividend and a dividend yield of 0.67%. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.40%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.